# Jack Cuzick

Source: https://onco.cc/people/jack-cuzick/  
OnCo record `jack-cuzick` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Epidemiologist who led IBIS-I and IBIS-II, proving tamoxifen and anastrozole prevent breast cancer in high-risk women.

## Summary

Jack Cuzick led the IBIS-I trial (tamoxifen) and IBIS-II (anastrozole) that established chemoprevention of breast cancer in high-risk women, and was the lead statistician of the ATAC trial that made aromatase inhibitors standard adjuvant therapy. He developed the Tyrer-Cuzick risk model and has led HPV-testing studies in cervical screening. His work continues on prevention and risk-based screening.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: prevention; epidemiology; breast
- Role: Professor of Epidemiology, Wolfson Institute of Population Health, Queen Mary University of London
- Specialisms: Breast cancer prevention; Screening epidemiology; Aromatase inhibitors; Risk prediction

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Cuzick%20J%5BAuthor%5D%20breast%20prevention

## Connected records

- cancers: [Cervical cancer](https://onco.cc/cancers/cervical/), [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/)
- technologies: [Chemoprevention & risk-reducing surgery](https://onco.cc/technologies/chemoprevention/), [Endocrine therapy (SERMs, AIs, SERDs)](https://onco.cc/technologies/endocrine-therapy/)
- institutions: [Barts Cancer Institute / Barts Health NHS Trust](https://onco.cc/institutions/barts-cancer-institute/)
- trials: [IBIS-I (International Breast Intervention Study I)](https://onco.cc/trials/ibis-i/), [IBIS-II (International Breast Intervention Study II)](https://onco.cc/trials/ibis-ii/)
- key papers: [IBIS-I: five years of tamoxifen keeps preventing breast cancer for at least 20 years](https://onco.cc/key-papers/paper-ibis-i-tamoxifen-lancet-oncol-2015/)

---
JSON: https://onco.cc/api/v1/entities/jack-cuzick.json